News

Study reveals new options

Bayer employees Ulrike Wolf and Christa Himmel (right) examine a Qlaira® pack at the Weimar Supply Center.

Zoom image

Bayer employees Ulrike Wolf and Christa Himmel (right) examine a Qlaira® pack at the Weimar Supply Center.

The novel oral contraceptive Qlaira® significantly reduced menstrual blood loss in a clinical study with women suffering from heavy and/or prolonged menstrual bleeding without organic pathology. The results of this international Phase III trial were presented by Professor Ian Fraser, the principal investigator, at the World Congress of the International Federation of Gynecology and Obstetrics in Cape Town. In a randomized, placebo-controlled and double-blind trial with 231 women in Europe and Australia, Qlaira® was compared to a placebo. The product also significantly improved iron metabolism parameters in these women.

Menstrual abnormalities such as heavy or prolonged uterine bleeding are very common. Said Dr. Phil Smits, Head of Women’s Healthcare at Bayer Schering Pharma: “The data from this study clearly underscore that our new oral contraceptive could offer a new treatment option for many women who suffer from these frequent gynecological symptoms.”